ANRO (Alto Neuroscience) Moat Score: 4/10 (As of Jun. 28, 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $27.04
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Moat Score?

Alto Neuroscience ANRO +6.88% 12 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,402 Biotechnology companies, Alto Neuroscience ranks better than 88.8% on this metric.

Alto Neuroscience has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Alto Neuroscience has Narrow Moat: Alto Neuroscience Inc has valuable intellectual property and patents in the neuroscience field, providing some protection. However, it lacks strong brand strength, customer loyalty, and significant market leadership. The company's competitive position is modest, with limited pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alto Neuroscience might have Narrow Moat - Discernible but modest moat.

Alto Neuroscience  (NYSE:ANRO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alto Neuroscience Moat Score Related Terms

ANRO vs MRVI, BBOT, REPL: Moat Score Comparison

For the Biotechnology subindustry, Alto Neuroscience's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Moat Score distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Moat Score falls into.


ANRO
12GF Score
Alto Neuroscience Inc ANRO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Alto Neuroscience (ANRO) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Alto Neuroscience ranks #157 out of 1402 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Alto Neuroscience's Moat Score too high?
Alto Neuroscience's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Alto Neuroscience's value of 4 is 100% above this industry median. Based on the distribution chart, Alto Neuroscience ranks #157 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Moat Score compare to MRVI and BBOT?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #157 out of 1402 companies for Moat Score. This places Alto Neuroscience in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Alto Neuroscience's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alto Neuroscience's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.04
Price